Ratings Bayer CropScience Limited NSE India S.E.

Equities

BAYERCROP

INE462A01022

Delayed NSE India S.E. 04:17:32 2024-04-30 am EDT 5-day change 1st Jan Change
5,560 INR +1.54% Intraday chart for Bayer CropScience Limited +0.05% +0.14%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.61 times its estimated earnings per share for the ongoing year.
  • With an enterprise value anticipated at 4.33 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Sector: Agricultural Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+0.14% 2.93B -
+15.82% 38.79B
C
-.--% 10.98B -
B+
-4.50% 7.52B
A
+4.44% 6.81B
B-
-3.63% 6B
B+
-10.52% 5.59B -
C-
-3.77% 5.66B
B
+33.14% 5.26B
B-
-12.64% 4.56B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality